Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 01, 2026 12:15 ET | Source: Rezolute, Inc.

Rezolute Announces Oral Presentation of Results From its Phase 3 sunRIZE Study of Ersodetug in Patients with Congenital Hyperinsulinism at the Pediatric Endocrine Society Annual Meeting

Includes results from additional continuous glucose monitoring (CGM)-based outcomes which demonstrate significant and consistent improvements in glycemic control in ersodetug treatment arms compared...
April 21, 2026 07:00 ET | Source: Rezolute, Inc.

Rezolute to Present Results from its Phase 3 sunRIZE Study in Congenital Hyperinsulinism at the Pediatric Endocrine Society (PES) Annual Meeting

Oral presentation will include previously announced topline results as well as pre-specified and post-hoc data updates REDWOOD CITY, Calif., April 21, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc....
March 24, 2026 07:00 ET | Source: Rezolute, Inc.

Rezolute Provides Update on its Congenital Hyperinsulinism Program Following FDA Meeting

REDWOOD CITY, Calif., March 24, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage rare disease company focused on treating hypoglycemia caused by all...
March 04, 2026 07:00 ET | Source: Rezolute, Inc.

Rezolute to Participate in the Citizens Life Sciences Conference

REDWOOD CITY, Calif., March 04, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage rare disease company focused on treating hypoglycemia caused by all...
February 12, 2026 16:05 ET | Source: Rezolute, Inc.

Rezolute Reports Second Quarter Fiscal 2026 Financial Results and Provides Business Update

REDWOOD CITY, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage rare disease company focused on treating hypoglycemia caused by all...
February 04, 2026 07:00 ET | Source: Rezolute, Inc.

Rezolute to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026

REDWOOD CITY, Calif., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage rare disease company focused on treating hypoglycemia caused by all...
January 07, 2026 07:00 ET | Source: Rezolute, Inc.

Rezolute Provides Insights from its Phase 3 sunRIZE Study in Congenital Hyperinsulinism and Shares Findings from its Expanded Access Program in Tumor Hyperinsulinism

Company believes that data from sunRIZE and the Expanded Access Program (EAP) provide evidence of activity of ersodetug in both indicationsCompany plans to meet with FDA to align on path forward for...
December 11, 2025 07:00 ET | Source: Rezolute, Inc.

Rezolute Announces Phase 3 sunRIZE Study Results in Congenital Hyperinsulinism

Study did not meet the primary or key secondary endpoint 45% reduction in hypoglycemia events observed at top ersodetug dose (10 mg/kg) compared to 40% improvement in placebo arm Management to host...
November 10, 2025 17:30 ET | Source: Rezolute, Inc.

Rezolute Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

REDWOOD CITY, Calif., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (NASDAQ: RZLT), (“Rezolute” or the “Company”), a late-stage rare disease company focused on treating hypoglycemia caused by...
November 06, 2025 16:05 ET | Source: Rezolute, Inc.

Rezolute Reports First Quarter Fiscal 2026 Financial Results and Provides Business Update

REDWOOD CITY, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage rare disease company focused on treating hypoglycemia caused by...